Unaudited Financial Results for the half year ended September 30,2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Adeshwar Meditex reported a decline in H1 FY26 performance, with revenue from operations falling about 26.5% to ₹3,005.78 lakhs from ₹4,089.59 lakhs a year ago. Profit after tax dropped to ₹73.10 lakhs from ₹90.41 lakhs, and EPS came in at ₹0.51 versus ₹0.63. Cost of materials consumed fell sharply from ₹3,561.58 to ₹2,315.58 lakhs, tracking lower revenue. Cash and cash equivalents plunged to just ₹4.72 lakhs from ₹329.71 lakhs last year, as the company used ₹674.59 lakhs in financing activities to reduce short-term borrowings. On governance, the board noted the demise of independent director Mr. Benegal Parameshwara Udpa and proposed appointing Mr. K. Raghupathi Bhat as a non-executive director, subject to DIN approval.
The lower top line and thinner profit, combined with a near-depletion of cash, signal weaker operating momentum and tighter liquidity, which may concern shareholders despite debt reduction efforts. The loss of an independent director creates a short-term governance gap, though the proposed appointment aims to fill it.